Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…Results In 2023 and 2024 we used seven immunotherapeutic drugs: pembrolizumab (230 patients), durvalumab (45 patients), atezolizumab (45 pati…
… of patients, and 12.5% had CNS metastases. Treatments included pembrolizumab (71.9%), nivolumab (21.9%) and durvalumab (6.3%); 71.9% receive…
…gical therapy (21%), and other (9%). Most implicated drugs were nivolumab, ipilimumab, carboplatin, paclitaxel, oxaliplatin, and pembroli…
…0 (95% CI, 0.45-0.81; p=0.0009) between EV-Pembrolizumab versus Nivolumab-CT. According to the ATE guide, these treatments presented a degre…
…ring may help identify patients who could benefit from extended osimertinib therapy, although further clinical validation is warranted.ctDN…
…-1 monotherapy, whereas anti-RPLP2 was associated with irAEs in ipilimumab/nivolumab combination therapy. For ir-colitis, 38 autoantibodie…
…programmed cell death protein 1 (PD-1) antibodies nivolumab and pembrolizumab significantly improved the survival of patients with melanoma w…
…tely diagnosed with bilateral epididymo-orchitis (EO) following pembrolizumab maintenance treatment. Our report adds to the three identified …
… who experienced a long-lasting complete response to first-line pembrolizumab, but subsequently relapsed after more than 4 years with an MSS …
…ounded 60 bags of 19 different drugs, including 5-fluorouracil, bevacizumab, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubic…
…Objectives Enfortumab vedotin and pembrolizumab (EV–Pem) have recently been shown to improve …
…ined endoscopic investigations and was treated empirically with Budesonide, having reported previous intolerance to Prednisolone, for pres…